CSIMarket
 


Nightstar Therapeutics Plc  (NITE)
Other Ticker:  
 

Cumulative Nightstar Therapeutics Plc's Working Capital Ratio for Trailing Twelve Months Period

NITE's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

NITE Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
(Jun 30 2018)
II. Quarter
(Dec 31 2017)
IV. Quarter
Y / Y Current Liabilities Growth -6.88 % -5.6 % 38.42 % 5.41 % -
Y / Y Current Assets Growth 24.46 % 32.78 % -15.99 % -10.57 % -
Working Capital Ratio for Trailing Twelve Months Period 42.13 39.11 35.5 40.53 42.19
Total Ranking # 337 # 294 # # #
Seq. Current Liabilities Growth -1.36 % -31.8 % 31.31 % 5.41 % 0 %
Seq. Current Assets Growth -6.26 % 58.06 % -6.07 % -10.57 % 0 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2019
On the trailing twelve months basis Nightstar Therapeutics Plc Current Assets average grew by 24.46% in I. Quarter year on year, while Current Liabilities decreased to $ 3 millions, this led to increase in in Nightstar Therapeutics Plc's Working Capital Ratio for Trailing Twelve Months Period to 42.13, Working Capital Ratio for Trailing Twelve Months Period remained below Nightstar Therapeutics Plc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry Nightstar Therapeutics Plc achieved highest Working Capital Ratio for Trailing Twelve Months Period. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about NITE
Working Capital Ratio NITE in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 0
Sector # 3
S&P 500 # 46


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
14.37 11.57 9.53
(Dec 31 2017)   (Mar 31 2019)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2019, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Nightstar Therapeutics Plc  47.96 
Adverum Biotechnologies Inc   43.24 
Dyadic International Inc  42.89 
Krystal Biotech Inc   40.65 
Kaleido Biosciences Inc   34.68 
Tcr2 Therapeutics Inc   30.91 
Palisade Bio Inc   30.26 
Iovance Biotherapeutics Inc   24.73 
Logicbio Therapeutics Inc   24.13 
Orchard Therapeutics Plc  23.07 
Enzon Pharmaceuticals inc   22.05 
Mosaic Immunoengineering Inc   21.98 
Acceleron Pharma inc  18.21 
Kodiak Sciences Inc   18.10 
Voyager Therapeutics Inc   17.93 
Fennec Pharmaceuticals Inc   17.45 
Regenxbio Inc   16.90 
Crispr Therapeutics Ag  16.78 
Allogene Therapeutics inc   16.65 
Cortexyme Inc   15.91 
Audentes Therapeutics Inc   15.30 
Avrobio Inc   13.79 
Allena Pharmaceuticals Inc.  13.16 
Atara Biotherapeutics Inc   12.97 
Denali Therapeutics Inc   12.69 
Organovo Holdings Inc   12.45 
Gritstone Bio Inc   12.25 
Solid Biosciences Inc   11.05 
Axcella Health Inc   11.03 
Bluebird Bio Inc   10.32 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com